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Background: The objective was to present a new ovarian response prediction index (ORPI), which was based on
anti-Müllerian hormone (AMH) levels, antral follicle count (AFC) and age, and to verify whether it could be a reliable
predictor of the ovarian stimulation response.
Methods: A total of 101 patients enrolled in the ICSI programme were included. The ORPI values were calculated
by multiplying the AMH level (ng/ml) by the number of antral follicles (2–9 mm), and the result was divided by the
age (years) of the patient (ORPI=(AMH x AFC)/Patient age).
Results: The regression analysis demonstrated significant (P<0.0001) positive correlations between the ORPI and the
total number of oocytes and of MII oocytes collected. The logistic regression revealed that the ORPI values were
significantly associated with the likelihood of pregnancy (odds ratio (OR): 1.86; P=0.006) and collecting greater than
or equal to 4 oocytes (OR: 49.25; P<0.0001), greater than or equal to 4 MII oocytes (OR: 6.26; P<0.0001) and greater
than or equal to 15 oocytes (OR: 6.10; P<0.0001). Regarding the probability of collecting greater than or equal to 4
oocytes according to the ORPI value, the ROC curve showed an area under the curve (AUC) of 0.91 and an efficacy
of 88% at a cut-off of 0.2. In relation to the probability of collecting greater than or equal to 4 MII oocytes
according to the ORPI value, the ROC curve had an AUC of 0.84 and an efficacy of 81% at a cut-off of 0.3. The ROC
curve for the probability of collecting greater than or equal to 15 oocytes resulted in an AUC of 0.89 and an
efficacy of 82% at a cut-off of 0.9. Finally, regarding the probability of pregnancy occurrence according to the ORPI
value, the ROC curve showed an AUC of 0.74 and an efficacy of 62% at a cut-off of 0.3.
Conclusions: The ORPI exhibited an excellent ability to predict a low ovarian response and a good ability to
predict a collection of greater than or equal to 4 MII oocytes, an excessive ovarian response and the occurrence of
pregnancy in infertile women. The ORPI might be used to improve the cost-benefit ratio of ovarian stimulation
regimens by guiding the selection of medications and by modulating the doses and regimens according to the
actual needs of the patients.
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For ovarian stimulation in in vitro fertilisation (IVF)
cycles, different protocols have been developed to induce
multifollicular development, which increases the number
of available oocytes and, thereby, the number of embryos
for selection and transfer [1]. However, the patients are
exposed to the possibility of a low or excessive ovarian
response. Furthermore, the possibility of a negative im-
pact of supraphysiological levels of oestrogen resulting
from the large numbers of follicles and oocytes on the
embryo quality and/or the endometrium has been repeat-
edly questioned [2-4]. For this reason, knowledge of the
patient’s potential ovarian response can help clinicians
individualise the medication dosage, which may reduce
the adverse effects of an excessive ovarian response, de-
crease the rate of cancelled cycles and ultimately, in-
crease the pregnancy rate.
The first indicator of the ovarian reserve taken into ac-
count is the patient’s age. Although the number and quality
of oocytes both decrease with age, the reproductive poten-
tial varies drastically among women of similar age; there-
fore, they might exhibit different responses to ovarian
stimulation [5]. Consequently, an individual’s chronological
age may not be as valuable a predictor of fertility as her
“biological age”, as defined by hormonal and functional pro-
files [6]. In fact, in addition to age, several clinical, endo-
crine and ultrasound markers, and dynamic tests have been
proposed for the prediction of the ovarian response to
stimulation [7,8]. Among these markers, use of the level of
anti-Müllerian hormone (AMH) and the antral follicle
count (AFC) is of particular interest [7-16]. The AFC con-
sists of the sum of follicles <10 mm in both ovaries on a
transvaginal ultrasound and has been used to predict the
ovarian reserve and the patient response to ovarian stimula-
tion. However, there is significant variation among different
authors in the limits used to classify antral follicles
[7,12,13,17-20]. AMH, a member of the transforming
growth factor-beta superfamily, is only produced by the
granulosa cells surrounding the pre-antral and small antral
follicles. Additionally, AMH is independent of follicle-
stimulating hormone (FSH), whereby its levels are a direct
measure of the follicular pool production. The serum levels
of AMH decrease throughout reproductive life and are un-
detectable in the postmenopausal period [14].
However, despite the predictive power that each marker
for the ovarian response may have individually, all of these
markers have errors associated with their estimation. In
fact, none of these parameters can be considered to be
undoubtedly reliable predictors of the number/quality of
the remaining oocytes in the ovary or the probability
of pregnancy following infertility treatment [17,21,22]. A
systematic review of tests predicting the ovarian reserve
and IVF outcomes [7] observed that the accuracy of the
so-called ovarian reserve tests in predicting the occurrenceof both a poor ovarian response and hyperstimulation
appears to be modest. Therefore, a prediction of the ovar-
ian response using a single biomarker may not be sufficient
for the formulation of a precise treatment plan.
Considering these observations, the main objectives of
the present study were to present a new ovarian response
prediction index (ORPI), which was based on the AMH,
AFC and age, and to verify whether such a marker could
be a reliable predictor of ovarian stimulation in assisted
reproductive technology (ART) cycles.
Methods
Patients
This study included 101 patients attending their first ICSI
(intracytoplasmic sperm injection) cycle at the Centre for
Human Reproduction “Prof. Franco Junior” between
March 2012 and August 2012. All patients satisfied the
following criteria: age ≤39 years, body mass index (BMI)
between 20–30 kg/m2, regular menstrual cycles, both
ovaries present, no history of ovarian surgery, no severe
endometriosis and no evidence of endocrine disorders.
The only exclusion criterion was the presence of ovarian
cysts as assessed by transvaginal ultrasound. The study
was authorised by the local ethical committee Institu-
tional Review Board, and a written informed consent was
obtained from all recruited subjects.
AMH measurement
A venous blood sample for an AMH measurement was
taken before the scheduled treatment (minimum of 30
days) during the early follicular menstrual cycle phase in
all women. AMH was measured using an enzymatically
amplified 2-site immunoassay kit (AMH Gen II ELISA,
Beckman Coulter Inc.) according to the manufacturer’s
manual. The lowest detection limit of this assay is 0.01
ng/ml, whereas the maximum intra- and inter-assay coef-
ficients of variation are 3.3% and 6.5%, respectively. To
minimise the chances of bias in the assay, all sera were
processed in duplicate during the same day, using the
same measurement kits, and by the same operator.
Low- and high-level controls were included in each assay.
Antral follicles count
All subjects had a transvaginal ultrasonographic evalu-
ation performed during the early follicular phase of a pre-
vious cycle before the scheduled treatment. A single
experienced sonographer, who was blinded to the results
of any hormonal assays and the patient’s age, performed
the evaluation using a conventional 2-dimensional trans-
vaginal ultrasound at 7 MHz (Medison Digital Color MT;
Medison Co. Ltd., Seoul, Korea). The total number of
2-9-mm antral follicles in both ovaries was used for the
calculations. The intra-observer coefficient of variation
was 1.0%.
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The patients were subjected to 2 schemes of controlled
ovarian stimulation, as follows: a long gonadotropin-
releasing hormone (GnRH) agonist (GnRH-a; n=60)
protocol or a multi-dose GnRH antagonist (GnRH-ant/
n=41) protocol. The selection of the stimulation proto-
col was at the discretion of the clinician.
GnRH-a protocol [23-27]: The pituitary downregulation
began during the luteal phase of the previous menstrual
cycle with the GnRH-a leuprolide acetate (leuprolide
acetate; LupronW; Abbott, Brazil) at a dose of 1 mg/day
for 14 days. The ovaries were then stimulated with a
fixed dose of 150–225 IU of recombinant FSH (rFSH;
Gonal FW; Serono, Brazil) and 75 IU/day of recombinant
luteinising hormone (rLH; LuverisW; Serono, Brazil) for a
period of 7 days. The decision on the starting dose of
FSH was based on patient’s age. On day 8 of the ovarian
stimulation, the follicular development was monitored
by a transvaginal ultrasound at 7 MHz. The rFSH dose
was modified according to the ovarian response, and the
rLH supplementation was increased to 150 IU/day when
one or more follicles measuring ≥10 mm in diameter
were found.
GnRH-ant protocol [23-27]: On day 3 of the cycle,
ovarian stimulation was induced with a fixed dose of
150–225 IU of rFSH and 75 IU/day of rLH for a period
of 5 days. The decision on the starting dose of FSH was
based on patient’s age. On day 8 of the menstrual cycle
(day 6 of ovarian stimulation), the follicular development
was monitored by a transvaginal ultrasound at 7 MHz.
The r-FSH dose was modified according to the ovarian
response, and the r-LH supplementation was increased
to 150 IU/day when 1 or more follicles measuring ≥10
mm in diameter were found. The GnRH-ant cetrorelix
(cetrorelix; CetrotideW; Serono, Brazil) was started at a
dose of 0.25 mg/day s.c. when at least 1 follicle of ≥14
mm was observed by the ultrasound.
To induce the final oocyte maturation in both protocols
(GnRH-a and GnRH-ant), 250 μg of recombinant human
chorionic gonadotropin (r-hCG; Ovidrel; Serono, Brazil)
was administered s.c. when at least 2 follicles reached a
mean diameter of ≥17 mm. GnRH-a and GnRH-ant were
administered until the day of the r-hCG injection. The
oocyte retrieval was performed by a transvaginal aspir-
ation under ultrasound guidance 34–36 hours following
the r-hCG injection.
Calculation of ovarian response prediction index (ORPI)
The ORPI values were calculated by multiplying the AMH
(ng/ml) level by the number of antral follicles (2–9 mm),
and the result was divided by the age (years) of the patient.
This definition of ORPI was based on previous evaluations
that found that the ovarian response to stimulation had
positive correlations with the AMH levels and number ofantral follicles and was negatively correlated with the
patient’s age. The derivation of ORPI was intuitive, based
on the observed correlations and testing of different combi-
nations. We sought a simple index that was easy to use in
daily practice and combined a small number of variables
whose association could potentiate the result of each indi-
vidual variable in predicting ovarian response to stimulation
and at the same time compensate for possible individual
deficiencies. The ORPI was defined by the following equa-
tion:ORPI=(AMH x AFC)/Patient age.
Notably, the calculated value of the ORPI in the study
was not influenced by the protocol choice for the induc-
tion of ovulation or the doses of gonadotropin.
Endpoints
The primary endpoints were the total number of oocytes
and the number of metaphase II (MII) oocytes retrieved.
The secondary endpoints were the number of follicles
≥10 mm, ≥16 mm and ≥18 mm on the day of HCG
administration and clinical pregnancy.
Statistical analysis
The data management and univariate analysis were per-
formed using the StatsDirect statistical software (Cheshire
UK). The values for the ORPI, age, AMH, AFC, total num-
ber of oocytes retrieved, number of MII oocytes and the
number of follicles ≥10 mm, ≥16 mm and ≥18 mm on the
day of hCG administration were treated as continuous vari-
ables for analysis.
The Mann–Whitney test, Student’s t-test and the chi-
square test were used when appropriate. Correlations were
performed using the Spearman’s rank correlation test. A
P<0.05 was considered statistically significant. A univariate
logistic regression was used to estimate the value of an
independent variable in predicting the likelihood of collect-
ing ≥4 oocytes (criterion for the classification as a poor
ovarian response) [22,28-30], collecting ≥4 MII oocytes,
collecting ≥15 oocytes (assessing excessive response)
[19,31-35] and clinical pregnancy (determined based on the
presence of a gestational sac accompanied by an image of
the embryonic/foetal cardiac activity on transvaginal ultra-
sounds 4 weeks after transfer). The odds ratio (OR) and
95% confidence interval (CI) constituted the descriptive
analysis.
Receiver operating characteristic (ROC) curves were
constructed to examine the performance of the ORPI in
predicting clinical pregnancy and the retrieval of ≥4
oocytes, ≥4 MII oocytes and ≥15 oocytes. An optimised
threshold was determined. The discriminative perform-
ance of the model was assessed by the area under the
curve (AUC) of the ROC curve. Sensitivity was defined
as the fraction of cycles in which the expected outcome
(clinical pregnancy and retrieval of ≥4 oocytes, ≥4 MII
oocytes and ≥15 oocytes) was predicted correctly, and
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resulting in the expected outcome that was predicted
correctly. StatsDirect requires the following 2 columns
of data for each ROC plot: a column with the test results
for cases where the condition being tested is known to
be present and another column with the test results for
known negative cases. The sensitivity is then plotted
against specificity. StatsDirect calculates the area under
the ROC curve directly using an extended trapezoidal
rule and by a non-parametric method that is analogous
to the Wilcoxon/Mann–Whitney test. A confidenceTable 1 General characteristics of the study population
General population (n=101) GnRH a
Age (years) 34.1±5.1 (21–39)
AMH (ng/ml) 1.8±1.8(0.01-9.6)
AFC (n) (2–9 mm) 12.5±6.2 (2–34)
ORPI 1.0±1.5(0–8.8)
BMI 24.6±4.1
Tobacco use 4% (4/101)
Regular alcohol use 1% (1/101)












Total dose FSH (UI) 1956±804
Total dose LH (UI) 982±351
Time of stimulation (days) 10.2±2.1






-Metaphase II stage 6.9±5.2
-Metaphase I stage 1.3±1.8
-Germinal vesicle stage 0.8±1.1
Clinical pregnancy rate 32.7% (33/101)
AMH: anti-Müllerian hormone ORPI: ovarian response prediction index.
AFC: antral follicle count BMI: body mass index.
ns: not significant.interval was constructed using DeLong’s variance
estimate.
Results
The general characteristics of the study population are
summarised in Table 1. Of all 101 women, the mean age
was 34.1±5.1 years (range 21–39), the mean AMH level
was 1.8±1.8 ng/mL (range 0.01-9.6) and the mean AFC
was 12.5±6.2 (range 2–34). The mean ORPI was 1.0±1.5
(range 0–8.8). Basic demographic characteristics such as
maternal age, BMI, duration of infertility, smoking, alcoholgonist protocol (n=60) GnRH antagonist protocol (n=41) P
34.1±5.4 (21–39) 34.1±4.7 (26–39) ns
1.5±1.3 (0.01-8.2) 2.3±2.2 (0.01-9.6) ns
11.8±5.3 (2–34) 13.6±7.1 (4–28) ns
0.7±1.2(0–8.8) 1.3±1.8(0–7.6) ns
24.0±4.1 25.6±3.8 ns
3.3% (2/60) 4.9% (2/41) ns
1.7% (1/60) 0/41 ns
5.1±3.6 4.1±2.7 ns
ns
41.6% (25/60) 26.8% (11/41)
20% (12/60) 34.1% (14/41)
16.7% (10/60) 19.5% (8/41)
15% (9/60) 9.8% (4/41)
3.3% (2/60) 4.9% (2/41)
1.7% (1/60) 4.9% (2/41)
1.7% (1/60) 0.0% (0/41)
ns
81.7% (49/60) 73.2% (30/41)











31.2% (19/60) 34.1% (14/41) ns
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(P>0.05) between the GnRH-a and GnRH-ant patient
groups. The distribution (P>0.05) of the main characteris-
tics of the ovarian stimulation cycle observed for the
GnRH-a and GnRH-ant groups were comparable.
The regression analysis demonstrated significant
(P<0.05) positive correlations between the ORPI and the
total number of oocytes collected (r=0.78), total number
of MII oocytes (r=0.70) and the number of follicles ≥10
mm (r=0.82), follicles ≥16 mm (r=0.67) and follicles ≥18
mm (r=0.56) on the hCG administration day. Addition-
ally, all the other markers of ovarian response showed
statistically significant correlations with the variables
analysed. However, the association provided by the ORPI
improved the correlation because the individual correl-
ation coefficients of each marker of ovarian response
(age, AMH and AFC) were always lower than that pre-
sented by the ORPI. When the analysis was performed
considering only the GnRH-a protocol group, the regres-
sion analysis also demonstrated significant (P<0.05) posi-
tive correlations between the ORPI and the total
number of oocytes collected, total number of MII
oocytes and the number of follicles ≥10 mm, ≥16 mm
and ≥18 mm. Similarly, the analysis considering only the
GnRH-ant protocol group also showed statistically sig-
nificant (P<0.05) correlations between the ORPI with all
variables analysed. Table 2 summarises these results.
The logistic regression analysis revealed that the ORPI
values were significantly associated with the likelihood of
clinical pregnancy (OR: 1.86; P=0.006) and of collecting
≥4 oocytes (OR: 49.25; P<0.0001), ≥4 metaphase II
oocytes (OR: 6.26; P<0.0001) and ≥15 oocytes (OR: 6.10;
P<0.0001). Alternatively, the logistic regression analysis
also revealed a statistically significant (P<0.05) association
between the number and maturity of collected oocytes
and the other prognostic factors analysed, including the
woman’s age (≥4 oocytes: OR: 0.76; ≥4 MII oocytes: OR:
0.80; ≥15 oocytes: OR: 0.79; clinical pregnancy: OR: 0.85),
AMH (≥4 oocytes: OR: 5.56; ≥4 MII oocytes: OR: 2.86;
≥15 oocytes: OR: 2.56; clinical pregnancy: OR: 1.53) and
AFC (≥4 oocytes: OR: 1.71; ≥4 MII oocytes: OR: 1.29; ≥15
oocytes: OR: 1.30; clinical pregnancy: OR: 1.14). However,
the odds ratios presented by the ORPI were always higher
(i.e., further from 1) than those presented by all other
prognostic factors. The results indicate that for each one
unit increase of the ORPI value, the chance of collecting
≥4 oocytes increases 49 times (or it increases by 4.9 times
for each increase of 0.1), 6 times for collecting ≥4 MII
oocytes ≥15 oocytes and 1.8 times for the occurrence of
clinical pregnancy. These results indicate that the ORPI
presents a predictive capability for the occurrence of
these events (collection of ≥4 oocytes, ≥4 MII oocytes
and ≥15 oocytes and pregnancy) that was higher than that
of each marker individually. As shown by the regressionanalysis, the results obtained when considering patients
undergoing GnRH-a protocol and GnRH-ant protocol in-
dividually replicated the pattern obtained for the total
population (the odds ratios presented by the ORPI were
always higher than those presented by all other prognos-
tic factors). Figure 1 summarises these results.
The performance of the ORPI as a prognostic test was
observed using ROC curves. Regarding the probability of
collecting ≥4 oocytes, the ROC curve showed an area
under the curve of 0.91 (95% CI: 0.84-0.98), indicating that
the ORPI had an excellent prognostic potency for this
point. Setting the threshold at 0.2 offered the optimal com-
promise between specificity (86%) and sensitivity (89%)
and between positive predictive value (96%) and negative
predictive value (68%). At this cut-off level, the efficacy of
the ORPI for collecting at least 4 oocytes was 88%. The
ROC curves also revealed good prognostic potency for all
other factors (Age, AMH and AFC) analysed. However, the
AUC presented by the ORPI was always higher than those
presented by all others factors. Figure 2A1 shows these
data. Despite small differences, considering the ROC
curves for GnRH-a and GnRH-ant groups individually
showed that the ORPI also exhibited an excellent ability to
predict collection of ≥4 oocytes (Figure 2A2 and 2A3).
Similarly, in regards to the probability of collecting ≥4
MII oocytes (Figure 2B), the ROC curve had an area under
the curve of 0.84 (95% CI: 0.75-0.93), indicating that the
ORPI also had a good prognostic potency for this issue.
Setting the threshold at 0.3 offered the optimal comprom-
ise between specificity (73%) and sensitivity (85%) and
between positive predictive value (86%) and negative pre-
dictive value (70%). At this cut-off level, the efficacy of the
ORPI for retrieval of at least 4 MII oocytes was 81%. The
ROC curves also revealed good prognostic potency for all
other factors (Age, AMH and AFC) analysed. However, the
AUC presented by the ORPI was always higher than those
presented by all others. Again, the ROC curves demon-
strate similar good results in the GnRH-a and GnRH-ant
groups (Figure 2B2 and 2B3) in regards to the probability
of collecting ≥4 MII oocytes.
In the same way, the ROC curve for the probability of
collecting ≥15 oocytes (Figure 2C) gave an area under the
curve of 0.89 (95% CI: 0.83-0.95), indicating that the
ORPI values in this situation had a good prognostic po-
tency. Setting the threshold at 0.9 offered the optimal
compromise between specificity (89%) and sensitivity
(86%) and between positive predictive value (96%) and
negative predictive value (68%). At this cut-off level, the
efficacy of the ORPI for collecting ≥15 oocytes was 82%.
The ROC curves also revealed good prognostic potency
for all other factors (Age, AMH and AFC) analysed. How-
ever, the AUC presented by the ORPI was always higher
than those presented by all others. Regarding the prob-
ability of collecting ≥15 oocytes, the ROC curves for the
Table 2 Correlation between predictors of the ovarian response (age, AMH, AFC and ORPI) and the total number of
oocytes collected, total number of MII oocytes collected and the number of follicles ≥10 mm, ≥16 mm and ≥18 mm at
the time of hCG administration
Ovarian response markers Variable Analyzed
Total oocytes collected
General population GnRH agonist group GnRH antagonist group
r 95% CI P r 95% CI P r 95% CI P
Age −0.49 −0.63 to −0.32 <0.0001 −0.44 −0.62 to −0.20 0.0004 −0.57 −0.75 to −0.31 <0.0001
AMH 0.72 0.60 to 0.80 <0.0001 0.74 0.60 to 0.84 <0.0001 0.70 0.50 to 0.83 <0.0001
AFC 0.72 0.61 to 0.81 <0.0001 0.67 0.50 to 0.79 <0.0001 0.80 0.66 to 0.89 <0.0001
ORPI 0.78 0.68 to 0.84 <0.0001 0.78 0.66 to 0.87 <0.0001 0.81 0.65 to 0.89 <0.0001
MII oocytes
General population GnRH agonist group GnRH antagonist group
r 95% CI P r 95% CI P r 95% CI P
Age −0.51 −0.64 to −0.34 <0.0001 −0.47 −0.65 to −0.24 0.0001 −0.58 −0.75 to −0.32 <0.0001
AMH 0.64 0.50 to 0.74 <0.0001 0.69 0.52 to 0.80 <0.0001 0.61 0.37 to 0.78 <0.0001
AFC 0.64 0.50 to 0.74 <0.0001 0.59 0.40 to 0.74 <0.0001 0.69 0.51 to 0.84 <0.0001
ORPI 0.70 0.57 to 0.78 <0.0001 0.74 0.59 to 0.83 <0.0001 0.70 0.48 to 0.83 <0.0001
Follicles ≥10 mm
General population GnRH agonist group GnRH antagonist group
r 95% CI P r 95% CI P r 95% CI P
Age −0.50 −0.64 to −0.33 <0.0001 −0.44 −0.62 to −0.20 0.0005 −0.60 −0.77 to −0.35 <0.0001
AMH 0.77 0.67 to 0.84 <0.0001 0.80 0.68 to 0.88 <0.0001 0.77 0.61 to 0.88 <0.0001
AFC 0.76 0.65 to 0.83 <0.0001 0.76 0.62 to 0.85 <0.0001 0.79 0.63 to 0.88 <0.0001
ORPI 0.82 0.74 to 0.87 <0.0001 0.86 0.76 to 0.91 <0.0001 0.81 0.72 to 0.91 <0.0001
Follicles ≥16 mm
General population GnRH agonist group GnRH antagonist group
r 95% CI P r 95% CI P r 95% CI P
Age −0.51 −0.65 to −0.35 <0.0001 −0.46 −0.64 to −0.23 0.0002 −0.62 −0.78 to −0.38 <0.0001
AMH 0.60 0.45 to 0.71 <0.0001 0.65 0.47 to 0.78 <0.0001 0.58 0.33 to 0.76 <0.0001
AFC 0.61 0.46 to 0.72 <0.0001 0.64 0.45 to 0.77 <0.0001 0.61 0.42 to 0.80 <0.0001
ORPI 0.67 0.53 to 0.76 <0.0001 0.72 0.56 to 0.82 <0.0001 0.67 0.45 to 0.81 <0.0001
Follicles ≥18 mm
General population GnRH agonist group GnRH antagonist group
r 95% CI P r 95% CI P r 95% CI P
Age −0.44 −0.59 to −0.26 <0.0001 −0.35 −0.56 to −0.10 0.0053 −0.66 −0.81 to −0.44 <0.0001
AMH 0.50 0.33 to 0.63 <0.0001 0.50 0.31 to 0.69 <0.0001 0.56 0.30 to 0.74 0.0001
AFC 0.52 0.35 to 0.65 <0.0001 0.52 0.32 to 0.70 <0.0001 0.62 0.38 to 0.78 <0.0001
ORPI 0.56 0.40 to 0.68 <0.0001 0.56 0.37 to 0.72 <0.0001 0.65 0.42 to 0.80 <0.0001
AMH: anti-Mullerian hormone; ORPI: ovarian response prediction index; AFC: antral follicle count;
CI: confidence interval.
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had a good prognostic potency for this point (Figure 2C2
and 2C3).
Finally, regarding the probability of pregnancy occur-
rence, the ROC curve showed an area under the curve of
0.74 (95% CI: 0.84-0.98), indicating that the ORPI had agood prognostic potency for this point. Setting the
threshold at 0.3 offered the optimal compromise between
specificity (47%) and sensitivity (93%) and between posi-
tive predictive value (46%) and negative predictive value
(94%). At this cut-off level, the efficacy of the ORPI for
pregnancy occurrence was 62%. ROC curves also revealed
Figure 1 Logistic regression analysis for the prognostic factors regarding the collected oocytes and pregnancy occurrence. A. Collection
of ≥4 oocytes. B. Collection of ≥4 MII oocytes. C. Collection of ≥15 oocytes. D. Clinical pregnancy.
Oliveira et al. Reproductive Biology and Endocrinology 2012, 10:94 Page 7 of 11
http://www.rbej.com/content/10/1/94good prognostic potency for all other factors (Age, AMH
and AFC) analysed. However, the AUC presented by the
ORPI was always higher than those presented by all other
factors. Figure 2D1 shows these data. Considering the
ROC curves for GnRH-a and GnRH-ant groups individu-
ally, the ORPI also exhibited a good ability to predict
clinical pregnancy (Figure 2D2 and 2D3).
Discussion
A reliable indicator for supplying more precise estimates
of the patients’ ovarian response might facilitate the op-
timisation and individualisation of assisted reproductive
treatment before the onset of a treatment cycle. The
present study proposes a new index, the ORPI, to iden-
tify the probable ovarian response to stimulation during
the ART cycles. The combination of different variables
in the ORPI resulted in a more precise index to predictthe ovarian response. Indeed, the results showed signifi-
cant correlations (P<0.001) between the ORPI values
and the number of obtained follicles and the number
and maturity of the collected oocytes. In addition, the
results using the ORPI were always better than those
results obtained using other predictive factors (AFC,
AMH and age) separately. These findings support the
use of this simple 3-variable index.
To the best of our knowledge, the present study is the
first to combine those 3 factors into one single index for
the assessment of the ovarian reserve. An estimate based
solely on age is not always sufficient to accurately predict
the ovarian response to gonadotropin stimulation, consid-
ering that the ovarian response is highly variable even
among women of a similar age [5]. This inter-individual
variation depends on the ovarian reserve of each person,
which is influenced by genetic and environmental factors
Figure 2 ROC Curve. The ROC curve analysis for ORPI as a prognostic factor regarding the collected oocytes and pregnancy occurrence. A.
Collection of ≥4 oocytes. B. Collection of ≥4 metaphase II (MII) oocytes. C. Collection of ≥15 oocytes. D. Clinical pregnancy.
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http://www.rbej.com/content/10/1/94that primarily determine the size of the pool of primordial
follicles at birth and the rate of the pool’s decline through-
out the reproductive life [36,37]. In addition, the number
of antral follicles can be assessed during a routine pelvic
ultrasound examination, which is an integral part of
the pretreatment assessment of women undergoing any
assisted reproduction treatment in almost all fertility units.Therefore, an ultrasound evaluation of the antral follicles
has gained acceptance as a good predictor of the ovarian
response with low intra- and inter-observer variations
[12,13], despite its routine use being hampered by the lack
of a standard methodology that would enable valid data
comparisons between different centres [6,38]. Based on
these observations, a joint analysis of age and the AFC
Oliveira et al. Reproductive Biology and Endocrinology 2012, 10:94 Page 9 of 11
http://www.rbej.com/content/10/1/94might combine their advantages and compensate for their
disadvantages, thus improving the assessment of ovarian
function. Indeed, upon attempting to develop prognostic
models for the identification of patients’ ovarian response,
la Cour Freiesleben et al. [39] found that the best prognos-
tic model to predict a low response included AFC and age.
In addition, the prediction of the ovarian response
could be further improved by including the serum AMH
levels into the calculation of the ORPI. Despite this test
not being universally available and recent alterations in
the methodology [14-16], the determination of the AMH
level consists of a simple blood test that can be per-
formed at any time during the menstrual cycle [40,41].
In contrast to the levels of FSH, LH and oestradiol, the
levels of AMH throughout the menstrual cycle show no
consistent fluctuation patterns [42]. Moreover, the ran-
dom fluctuations were small, indicating that AMH can be
used as a reliable and cycle-independent marker for the
ovarian reserve [16,43-45]. AMH appears to have a strong
association with the ovarian response to stimulation, as
shown by several authors [10,18,19,46-50], and it was
eventually suggested for use in individualising the regi-
mens for ovulation stimulation based on the AMH values
[31-33]. In 2 meta-analyses, Broe et al. [34,35] found that
AMH exhibits the same level of precision as the AFC for
predicting poor ovarian response and excessive respon-
ders to ovarian stimulation. Jayaprakasan et al. [10]
emphasised that AMH and AFC might replace each other
as the best predictors of a poor ovarian response.
The simplicity of the calculation, which requires clini-
cians to perform simple mathematical operations using
the variable values directly, and a direct correlation with
the results are the major strong points of the ORPI.
Other published studies also aimed to assess the ovarian
response by combining variables [9,11,20,22,39]. How-
ever, either these formulas were too complex compared
to the simplicity of the ORPI [9,24] or a wide variety of
variables were included, which made the assessment
complex [11,20,22]. Other studies [51,52] described an
index whose calculation required at least 1 cycle ofTable 3 The deployment of the ovarian stimulation protocol
groups categorised by the ovarian response prediction index




≥0.9 ≥15treatment. Conversely, another advantage of the ORPI is
its ability to estimate the ovarian response before the
onset of any treatment.
The present study has potential limitations. First, despite
recruiting all eligible participants during the study period,
the sample size is limited. This point is particularly import-
ant in regards to how the outcomes relate to clinical preg-
nancy. Despite the good results observed, the relationship
will strengthen with analysis of larger numbers of cycles/
patients. Second, FSH dose adjustments after the first
ultrasound did not follow a strict protocol. Third, the study
is not randomized trail and there is a possibility of bias
due to the difference in the sample size between GnRH
agonist and GnRH antagonist group. However, it should
be noted that all analyzes showed no differences between
the two protocols. Finally, despite basing our response defi-
nitions on numbers found in published studies, different
reproduction clinics may prefer other definitions for low/
excessive ovarian responses, which could modify the cut-
offs indicated. These limitations indicate that the ORPI
thresholds observed in our study could be prospectively
further re-evaluated. However, considering the good results
that our study showed, the thresholds of ORPI can be used
for counselling clinicians regarding the realistic chances of
pregnancy for patients.
There is no conventional ovarian stimulation regimen
universally useful for every single patient. Based on its pre-
dictive potential, the ORPI might be used as a tool in the
individualised planning of the medication doses and/or
ovarian stimulation regimens. Based on the cut-off points
obtained by the ROC curve analysis, we suggest several
stimulation regimens grounded on the results of the ORPI.
Table 3 summarises these stimulation protocols and the
FSH doses to be used according to the range of calculated
ORPI values with a particular focus on the extreme points
of the ovarian response. ORPI values of <0.2 were shown to
have the best sensitivity (86%) and specificity (89%) in pre-
dicting a poor ovarian responder. Similarly, an ORPI of
≥0.9 was shown to have the best sensitivity (89%) and speci-
ficity (86%) in predicting a high ovarian responder. In theseand doses of follicle-stimulating hormone (FSH) in the
(ORPI)
Protocol Dose of FSH
-GnRH Antagonist
-Short GnRH Agonist










-GnRH Antagonist 112.5 IU-75 IU
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http://www.rbej.com/content/10/1/94cases, the use of protocols including GnRH antagonists and
regimens with low-dose gonadotropin were recommended
to reduce the ovarian response and minimise the occur-
rence and/or severity of ovarian hyperstimulation syndrome
[53].
Conclusions
To summarise, the present study describes a new ORPI,
which is a simple 3-variable index that exhibits an excellent
ability to predict a low ovarian response (AUC: 0.91) and a
good ability to predict the collection of >4 MII oocytes
(AUC: 0.84) and an excessive ovarian response (AUC: 0.89)
in infertile women. The ORPI might be used to improve
the cost-benefit ratio of ovarian stimulation regimens by
guiding the selection of medications and by tailoring the
doses and regimens to the actual needs of patients.
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